[Skip to Content]
[Skip to Content Landing]
Editorial
April 16, 2003

Is Leukoreduction of Blood Components for Everyone?

Author Affiliations

Author Affiliations: Departments of Anesthesiology (Dr Corwin), Medicine (Drs Corwin and AuBuchon), and Pathology (Dr AuBuchon), Dartmouth-Hitchcock Medical Center, Lebanon, NH.

JAMA. 2003;289(15):1993-1995. doi:10.1001/jama.289.15.1993

For most of the last half-century, blood transfusion has been looked upon as relatively "risk free" and with obvious clinical benefit.1 A dramatic change in thinking occurred in the early 1980s, when concerns about transfusion-related infections, particularly those caused by hepatitis C virus and the human immunodeficiency virus (HIV), prompted reevaluation of the risks of allogeneic transfusion. Advances in transfusion medicine have greatly decreased the risk of viral transmission through blood transfusion; however, the approach to blood transfusion continues to be directed toward achieving a zero-risk blood supply.2 Over the last several years attention has focused on the advisability of the universal application of leukoreduction to the blood supply.

First Page Preview View Large
First page PDF preview
First page PDF preview
×